PHYSICIAN REPORTED TREATMENT ATTRIBUTES CONSIDERED IN FIRST-LINE AND PERCEPTIONS AROUND BRUTON TYROSINE KINASE INHIBITOR (BTKI) TREATMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) IN THE US

被引：0
|
作者：
Jensen, C. [1 ]
Ding, Z. [2 ]
Greenwood, T. [3 ]
Kluth, C. [3 ]
Sanderson, I [3 ]
Milloy, N. [3 ]
Mavani, H. [2 ]
Khan, W. [2 ]
Qureshi, Z. P. [2 ]
机构：
[1] Univ N Carolina, Div Hematol, Chapel Hill, NC USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Adelphi Real World, Bollington, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO102
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Mike
    Pham, Hoa
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Michael
    Hoa Pham
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir
    BLOOD, 2023, 142
  • [3] Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Greco, FA
    BLOOD, 2001, 98 (11) : 363A - 363A
  • [4] Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
    Wang, Lin
    Hartley, Louise
    Hawe, Emma
    Kangappaden, Teresa
    Laidlaw, Alyshia
    Sharman, Jeff
    LEUKEMIA & LYMPHOMA, 2023, 64 : S54 - S55
  • [5] Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
    Tuncer, Hande H.
    Ghosh, Nilanjan
    Fleury, Isabelle
    Leslie, Lori A.
    Manzoor, Beenish S.
    Lamanna, Nicole
    Eyre, Toby A.
    Hill, Brian T.
    Brown, Jennifer R.
    Sinai, Wendy
    Coombs, Catherine C.
    Ujjani, Chaitra
    Roeker, Lindsey E.
    Emechebe, Nnadozie
    Barr, Paul M.
    Davids, Matthew S.
    Martinez-Calle, Nicolas
    Rhodes, Joanna M.
    Lansigan, Frederick
    Pearson, Laurie
    Choi, Yun
    Schuster, Stephen J.
    Skarbnik, Alan P.
    Fakhri, Bita
    Coyle, Michael
    Stephens, Deborah M.
    Thompson, Meghan C.
    Jensen, Christopher E.
    Marx, Steven E.
    Jawaid, Dureshahwar
    Schuh, Anna
    Pivneva, Irina
    Watson, Talissa
    Guerin, Annie
    Shadman, Mazyar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S357 - S358
  • [6] Treatment Patterns and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated With Bruton's Tyrosine Kinase Inhibitors (BTKis) in US Community Setting
    Mitul, Gandhi
    Sudeep, Karve
    Bhavini, Srivastava
    Ding, He
    Diala, Harb
    Olga, Ryan
    Juliet, Ndukum
    Ari, Marcus
    Ira, Zackon
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S56 - S56
  • [7] Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)
    Lin, Kevin H.
    Huynh, Lynn
    Yang, Xiaoqin
    Zanardo, Enrico
    Matay, Lisa
    Pinaire, Megan
    Liborski, Daria
    McDonough, Mikaela M.
    Foreman, Jillian
    Farooqui, Mohammed Z. H.
    De Nigris, Enrico
    Gandra, Shravanthi R.
    Sarpong, Eric M.
    Duh, Mei Sheng
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2023, 142
  • [8] Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
    Archibald, William J.
    Barcellos, Anna
    Ambrose, Jacob
    Belli, Andrew J.
    Fernandes, Laura
    Hansen, Eric
    Wang, Ching-Kun
    Barr, Paul M.
    BLOOD, 2022, 140 : 4142 - 4143
  • [9] Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Choksi, Rushir J.
    Hou, Jing-Zhou
    Li, John
    Gart, Mike
    Vasudevan, Anupama
    Blanc, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    VALUE IN HEALTH, 2021, 24 : S38 - S38
12345